Cetuximab
KRAS Mutant Solid Tumors
Treeline Biosciences, Inc.monoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the KRAS Mutant Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Treeline Biosciences, Inc. | Phase 1 | CC |
Tln-372 Treeline Biosciences, Inc. | Phase 1 | CC |
Same molecule, other indications
Cetuximab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →